NIMG-49RESPONSE ASSESSMENT OF BEVACIZUMAB FOR MALIGNANT GLIOMA BY USING11C-METHIONINE AND18F-FLUOROMISONIDAZOLE PET TRACERS
| Autor: | Tetsuhiro Hatakeyama, Masaki Okada, Masaaki Kouchi, Takashi Tamiya, Keisuke Miyake, Aya Shinomiya, Daisuke Ogawa |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
Treatment response 18F-Fluoromisonidazole Bevacizumab business.industry 11c methionine medicine.disease Oncology Glioma medicine Biomarker (medicine) Neurology (clinical) Pet tracer Nuclear medicine business Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology FMISO medicine.drug |
| Zdroj: | Neuro-Oncology. 17:v165.1-v165 |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/nov225.49 |
| Popis: | OBJECTIVE: Use of the positron imaging agents, such as 11C-Methionine (MET) and 18F-Fluoromisonidazole (FMISO), is expected to lead the way for novel applications aimed at achieving efficient malignancy grading and treatment of gliomas. The aim of this study was to assess MET and FMISO PET studies to evaluate the biological effects induced by bevacizumab therapy in patients treated for high grade gliomas. METHODS: Twenty-two patients with high grade gliomas were treated biweekly with bevacizumab from July 2013 to May 2015. MR images, as well as MET and FMISO PET scans were obtained at baseline and at follow-up (4 weeks after treatment onset). MRI treatment response was evaluated by T1/T2 volumetry according to the response assessment in neuro-oncology (RANO) criteria. Based on the RANO criteria, we divided the patients into three groups (PR, SD, and PD), and compared changes of MET T/N ratio or FMISO T/B ratio between baseline and follow-up. These PET response assessments were compared in relation to PFS and OS. RESULTS: At the follow-up, MRI showed PR in 6 of 22 patients, SD in 11 of 22 patients, and PD in 5 of 22 patients. The median PFS were 13.1 months, 13.5 months and 2.4 months for PR, SD and PD, respectively. The median OS were 14.6 months, 14.5 months and 5.7 months for each group. MET and FMISO images in the PD group had a tendency to show the increase of changes. FMISO images in the SD group revealed 3 of 11 increased changes (15.1% up) and 8 of 11 decreased changes (11% down). The median PFS were 2.4 months and 16.3 months for each change, and the median OS were 9.8 months and 16.8 months. CONCLUSION: Decreased changes in FMISO-PET after bevacizumab therapy may be a useful biomarker for predicting PFS and OS in high-grade gliomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|